Geron surges after winning first US FDA approval for blood disorder drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Geron Corp (NASDAQ: GERN) | Delayed: 1.13 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.13 | 52 Week High | $5.30 | |||
| Open | $1.15 | 52 Week Low | $1.81 | |||
| Day High | $1.15 | P/E | N/A | |||
| Day Low | $1.11 | EPS | $-0.35 | |||
| Volume | 485,506 | |||||
